publication date: Oct. 20, 2016
October 2016 PDF
Non-Small Cell Lung Cancer Phase III Tecentriq Study Shows Better Survival vs. Chemo Regardless of PD-L1 Status
Genentech said its pivotal phase III OAK study of Tecentriq (atezolizumab) showed a median survival of 13.8 months, 4.2 months longer than those treated with docetaxel chemotherapy (median overall survival [OS]: 13.8 vs. 9.6 months; HR = 0.73, 95% CI: 0.62 – 0.87).
The results were presented at the European Society of Medical Oncology 2016 Annual Meeting in Copenhagen.
The OAK study evaluated people with non-small cell lung cancer whose disease had progressed on or after treatment with one or more platinum-based chemotherapy (second-line and third-line).
Patients Getting Gilotrif vs. Iressa in Phase IIb Study Had Higher PFS Radiation Therapy Improved Survival Rates for Early Stage Lung Cancer Melanoma Yervoy Improved OS in Fully Resected Stage III Patients from Phase III Study
Bristol-Myers Squibb Co. announced superior efficacy for Yervoy 10 mg/kg versus placebo on all survival endpoints in the phase III trial CA184-029 (EORTC 18071) evaluating stage III melanoma … Continue reading CCL Oct 2016
To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us
and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.